Difference between revisions of "Ibandronate (Boniva)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA")
m
Line 14: Line 14:
 
==Also known as==
 
==Also known as==
 
*'''Generic names:''' ibandronate sodium, ibandronic acid
 
*'''Generic names:''' ibandronate sodium, ibandronic acid
*'''Brand names:''' Bandrobon, Bandrone, Bondenza, Bondronat, Bonviva, Femorel
+
*'''Brand names:''' Bandrobon, Bandrone, Bondenza, Bondronat, Boniva, Bonviva, Femorel
  
 
==References==
 
==References==

Revision as of 14:22, 9 December 2020

General information

Class/mechanism: Bisphosphonate, inhibits osteoclast activity, dissolution of hydroxyapatite crystals, and bone resorption/turnover.[1][2][3][4][5]
Route: PO, IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

Also known as

  • Generic names: ibandronate sodium, ibandronic acid
  • Brand names: Bandrobon, Bandrone, Bondenza, Bondronat, Boniva, Bonviva, Femorel

References